Page 160 - Eceptor News Today

In a new study, researchers designed artificial intelligence (AI)-based primers for the SARS-CoV-2 Omicron variant.

A University of South Florida Health preclinical study offers molecular insight into how activated protein C (APC) may improve aging patients' tolerance to reperfusion injury – a potentially adverse effect of treatment for ischemic heart disease.

In a new study, a team of researchers assessed the neutralizing activity of XAV-19, a glyco-humanized polyclonal antibody derived from hyperimmunized animal hosts, against the SARS-CoV-2 Omicron variant.

In a new study, a team of researchers used cryo-electron microscopy to determine the spike (S) structures of the SARS-CoV-2 Omicron variant to understand how the mutations that alter its primary sequence impact S conformation.

Researchers assess the effectiveness and safety outcomes of interleukin-1 blocking agents in the treatment of COVID-19.

Exogenous trypsin treatment boosts SARS-CoV-2 infection in Vero E6 cells and promotes viral multiplication in cultured cells.

In a new study, researchers analyzed the effect of vaccine booster doses against the SARS-CoV-2 Omicron variant.

Researchers describe the kinetics of SARS-CoV-2-specific serum antibodies in convalescent children over six months following infection.

A new paper in the journal Molecules describes this in molecular terms, comparing SARS-CoV-2 with an earlier highly pathogenic coronavirus, SARS-CoV.

Researchers demonstrate how cytotoxic T-lymphocytes (CTLs) with specificity for SARS-CoV-2 eliminate multiple infected targets.